Cablivi® (caplacizumab-yhdp)

Cablivi (caplacizumab‑yhdp) is covered only for adults (≥18) with acquired TTP when used in combination with plasma exchange and immunosuppressive therapy (not covered as monotherapy or outside this combination). Coverage requires inpatient initiation with plasma exchange, prescription by or consultation with a hematologist, current use of ≥1 immunosuppressive agent, ≤2 prior aTTP recurrences while on Cablivi, adherence to the specified dosing schedule (11 mg IV ≥15 min before plasma exchange on day 1, 11 mg SC after plasma exchange day 1 then 11 mg SC daily), approval limited to 2 months and ≤60 doses after the last plasma exchange, and supporting documentation of diagnosis, inpatient initiation, hematology involvement, and concurrent immunosuppression.

"Treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy (FDA-approved indication)."